Correlation Between Veracyte and Zymeworks Common

Can any of the company-specific risk be diversified away by investing in both Veracyte and Zymeworks Common at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Veracyte and Zymeworks Common into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Veracyte and Zymeworks Common Stock, you can compare the effects of market volatilities on Veracyte and Zymeworks Common and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Veracyte with a short position of Zymeworks Common. Check out your portfolio center. Please also check ongoing floating volatility patterns of Veracyte and Zymeworks Common.

Diversification Opportunities for Veracyte and Zymeworks Common

0.25

Correlation Coefficient

Veracyte  Zymeworks Common

Modest diversification

The 3 months correlation between Veracyte and Zymeworks is 0.25. Overlapping area represents the amount of risk that can be diversified away by holding Veracyte and Zymeworks Common Stock in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Zymeworks Common Stock and Veracyte is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Veracyte are associated (or correlated) with Zymeworks Common. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Zymeworks Common Stock has no effect on the direction of Veracyte i.e., Veracyte and Zymeworks Common go up and down completely randomly.

Pair Corralation between Veracyte and Zymeworks Common

Given the investment horizon of 90 days Veracyte is expected to under-perform the Zymeworks Common. In addition to that, Veracyte is 1.26 times more volatile than Zymeworks Common Stock. It trades about -0.26 of its total potential returns per unit of risk. Zymeworks Common Stock is currently generating about -0.1 per unit of volatility. If you would invest  1,460  in Zymeworks Common Stock on December 2, 2024 and sell it today you would lose (120.00) from holding Zymeworks Common Stock or give up 8.22% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Veracyte  vs.  Zymeworks Common Stock

Veracyte

Risk-Adjusted Performance

Very Weak

Over the last 90 days Veracyte has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Zymeworks Common Stock

Risk-Adjusted Performance

Very Weak

Over the last 90 days Zymeworks Common Stock has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound primary indicators, Zymeworks Common is not utilizing all of its potentials. The recent stock price tumult, may contribute to shorter-term losses for the shareholders.

Pair Trading with Veracyte and Zymeworks Common

The main advantage of trading using opposite Veracyte and Zymeworks Common positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Veracyte position performs unexpectedly, Zymeworks Common can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Zymeworks Common will offset losses from the drop in Zymeworks Common's long position.

The idea behind Veracyte and Zymeworks Common Stock pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.